Science Explorer Back to mapMap

Most cited papers from SciClone Pharmaceuticals (United States)

What are the most cited papers from SciClone Pharmaceuticals (United States)?

The most cited paper from SciClone Pharmaceuticals (United States) is "mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt" (Kathryn E O'Reilly, F. Rojo, Qing‐Bai She et al., 2006), with 2,599 citations. Next come "Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth" (1,864) and "Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors" (1,195).

Showing 50 of 62 papers. Every paper with more than 27 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Kathryn E O'Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research Open access Feb 2006 2,599
2 Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth David C. Lyden, Koichi Hattori, Sérgio Dias et al. · Nature Medicine Nov 2001 1,864
3 Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors Ricky T. Tong, Yves Boucher, Sergey V. Kozin et al. · Cancer Research Open access Jun 2004 1,195
4 Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration Bert Oosthuyse et al. · Nature Genetics Jun 2001 1,016
5 Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 Monica Autiero et al. · Nature Medicine 8 Jun 2003 774
6 Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment Koichi Hattori, Beate Heissig, Yan Wu et al. · Nature Medicine Open access Jul 2002 635
7 Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors Chris Folkins, Shan Man, Ping Xu et al. · Cancer Research 15 Apr 2007 384
8 Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1 Chris Folkins, Yuval Shaked, Shan Man et al. · Cancer Research Open access 8 Sep 2009 378
9 Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy Larry Witte, Daniel J. Hicklin, Zhenping Zhu et al. · Cancer and Metastasis Reviews Review Jun 1998 310
10 Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma Cells Anthony D. Yang, Ernest Ramsay Camp, Fan Fan et al. · Cancer Research 2006 291
11 Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia Marcela Franco, Shan Man, Limor Chen et al. · Cancer Research Apr 2006 162
12 Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Guido Bocci, Shan Man, Shane K. Green et al. · Cancer Research 15 Sep 2004 161
13 Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity Z Zhu, Koichi Hattori, H Zhang et al. · Leukemia Mar 2003 158
14 Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice Andrew R. Reynolds, Louise E. Reynolds, Tobi Nagel et al. · Cancer Research Open access Dec 2004 154
15 Strategies for Delaying or TreatingIn vivoAcquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Jeanne M. du Manoir, Giulio Francia, Shan Man et al. · Clinical Cancer Research Open access Feb 2006 144
16 A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens Urban Emmenegger, Shan Man, Yuval Shaked et al. · Cancer Research Jun 2004 135
17 The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells Michel Jourdan, Martine Ferlin, Éric Legouffe et al. · British Journal of Haematology Open access Mar 1998 135
18 Angiogenesis Inhibition by Vascular Endothelial Growth Factor Receptor-2 Blockade Reduces Stromal Matrix Metalloproteinase Expression, Normalizes Stromal Tissue, and Reverts Epithelial Tumor Phenotype in Surface Heterotransplants Silvia Vosseler, Nicolae Mirancea, Peter Böhlen et al. · Cancer Research Open access 15 Feb 2005 129
19 Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer Harlan W. Waksal · Cancer and Metastasis Reviews Review Dec 1999 126
20 Polymorphisms inCyclooxygenase-2andEpidermal Growth Factor ReceptorAre Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab Georg Lurje, Fumio Nagashima, Wu Zhang et al. · Clinical Cancer Research Open access Dec 2008 115
21 Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer Peggy Stock, Dulabh Kaur Monga, Xinping Tan et al. · Molecular Cancer Therapeutics Open access 30 Jun 2007 108
22 Development of Heparanase Inhibitors for Anti-Cancer Therapy Zhenping Zhu, Elizabeth C. Navarro, Paul H. Kussie et al. · Current Medicinal Chemistry 24 Jul 2006 106
23 Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Fang Liao, Jacqueline F. Doody, Jay P. Overholser et al. · PubMed May 2002 105
24 Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases Thomas J. Kelly, Larry J. Suva, Yan Huang et al. · Cancer Research Open access Jul 2005 104
25 Vascular endothelial growth factor receptor‐1 in human cancer Jonathan D. Schwartz, Eric Keith Rowinsky, Hagop Youssoufian et al. · Cancer Open access 2 Feb 2010 95
26 Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation Gregory W. Allen, Corey Saba, Eric A. Armstrong et al. · Cancer Research Feb 2007 94
27 Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor Zhenping Zhu, Larry Witte · Investigational New Drugs Aug 1999 94
28 Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature Chad May, Jacqueline F. Doody, Rashed Abdullah et al. · Blood 9 Feb 2005 91
29 Monoclonal antibody therapeutics and apoptosis Dale L. Ludwig, DANIEL SANTIAGO PEREIRA, Zhenping Zhu et al. · Oncogene 8 Dec 2003 83
30 Lack of detection of agonist activity by antibodies to platelet‐derived growth factor receptor α in a subset of normal and systemic sclerosis patient sera Nick Loizos, Leah M. LaRiccia, Jami Weiner et al. · Arthritis & Rheumatism 30 Mar 2009 82
31 Immune Modulation with Thymosin Alpha 1 Treatment R. King, Cynthia W. Tuthill · Vitamins and hormones Book chapter 2016 77
32 In vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy Li Ma, Giulio Francia, Alicia Viloria‐Petit et al. · Cancer Research Open access 15 Jun 2005 75
33 Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study Kathleen M. Loomes, Robert H. Squires, Deirdre Anne Kelly et al. · Hepatology Communications Open access 4 May 2022 69
34 Activation of IKK by thymosin α1 requires the TRAF6 signalling pathway Ping Zhang, Justin Chan, Ana‐Maria Dragoi et al. · EMBO Reports Open access 20 May 2005 62
35 Clinical Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor and Its Receptors as Cancer Therapeutics Zhenping Zhu, Peter Böhlen, Larry Witte · Current Cancer Drug Targets Jun 2002 62
36 Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro Pieter Koolwijk, Erna Peters, B. van der Vecht et al. · Angiogenesis Mar 2001 62
37 Fetal Stromal–Dependent Paracrine and Intracrine Vascular Endothelial Growth Factor-A/Vascular Endothelial Growth Factor Receptor-1 Signaling Promotes Proliferation and Motility of Human Primary Myeloma Cells Loi͏̈c Vincent, David K. Jin, Matthias A. Karajannis et al. · Cancer Research 15 Apr 2005 60
38 The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial S Iino, Jouji TOYOTA, H. Kumada et al. · Journal of Viral Hepatitis 4 Apr 2005 58
39 Effects of Arginine on Photostability and Thermal Stability of IgG1 Monoclonal Antibodies Haripada Maity, Courtney O’Dell, Rahul Srivastava et al. · Current Pharmaceutical Biotechnology 29 Nov 2009 57
40 Cloning, genetic characterization, and chromosomal mapping of the mouse VDUP1 gene Dale L. Ludwig, Helen Kotanides, Thanh Thien Le et al. · Gene May 2001 53
41 Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells Matthias A. Karajannis, Loi͏̈c Vincent, Roberto DiRenzo et al. · Leukemia 6 Apr 2006 51
42 Single Variable Domain-IgG Fusion Juqun Shen, Marie Danielle Vil, Xenia Jimenez et al. · Journal of Biological Chemistry Open access 16 Feb 2006 50
43 Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody Zhenping Zhu, Dan Lu, Helen Kotanides et al. · Cancer Letters Mar 1999 49
44 Inhibitory Anti-FLT3 Antibodies Are Capable of Mediating Antibody-Dependent Cell-Mediated Cytotoxicity and Reducing Engraftment of Acute Myelogenous Leukemia Blasts in Nonobese Diabetic/Severe Combined Immunodeficient Mice Obdulio Piloto, Mark J. Levis, David L. Huso et al. · Cancer Research 15 Feb 2005 48
45 A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis* Nael A. McCarty, Thomas A. Standaert, M. Teresi et al. · Pediatric Pulmonology 15 Jan 2002 48
46 Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Zhichao Zhou, Marcela Fabiana Bolontrade, Krishna Reddy et al. · Clinical Cancer Research Open access 15 Aug 2007 47
47 In vitro effect of thymosin‐α1 and interferon‐α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C Pietro Andreoné, Carmela Cursaro, Annagiulia Gramenzi et al. · Journal of Viral Hepatitis Open access May 2001 46
48 Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Simon Pacey, Mark J. Ratain, Keith T. Flaherty et al. · Investigational New Drugs 17 Dec 2009 46
49 Bioactive recombinant human lactoferrin, derived from rice, stimulates mammalian cell growth Nancy Huang, Delia R. Bethell, Catherine M. Card et al. · In Vitro Cellular & Developmental Biology - Animal Open access 18 Sep 2008 45
50 Bead-to-bead transfer of chinese hamster ovary cells using macroporous microcarriers Sten Ohlson, J. Branscomb, Karin Nilsson · Cytotechnology 1994 45

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.